Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of α-particle-emitting 211At-labeled trastuzumab☆
To access this article, please choose from the options below
☆ This work was supported by Grants CA42324 and NS20023 from the National Institutes of Health and Grant DOE-FG02-08ER64697 from the Department of Energy.
PII: S0969-8051(09)00087-0
doi:10.1016/j.nucmedbio.2009.04.003
© 2009 Elsevier Inc. All rights reserved.
